Diagnostic Tests and Surveillance

There is no approved laboratory test able to detect the disease in live animals.
Veterinary pathologists confirm BSE by microscopic examination of brain tissue.

Extensive testing of bovine materials using a mouse bioassay have failed to detect BSE in muscle, meat or milk; BSE infectivity has been detected only in brain, spinal cord and retina. As a test for BSE infectivity, intracerebral inoculation is 1000 times more sensitive than the standard mouse assay (SEAC, Nov. 18, 1996). No infectivity has been detected in lymph tissue or spleen using this more sensitive test. Lymph and spleen are suspect tissues because they are infective in sheep. Results using more sensitive tests on meat, milk, tallow and gelatin have not yet been reported.

Despite recent publicity about a possible detection method the test is not specific for BSE. The presence of 14-3-3 brain protein in cerebrosplinal fluid indicates nerve cell death and may result from inflammatory brain disease (BSE is not inflammatory), herpes, encephalitis or coronary infarction.

van Keulen et al. developed antibodies to selected synthetic PrP based peptides in 1995 . Schreuder et al. used these antibodies to detect PrPsc in the tonsils of a group (n=55) of sheep naturally infected with scrapie (clinically positive for scrapie based on immunohistochemistry). This antibody was then used to detect scrapie in sheep during the preclinical phase of infection in susceptible sheep. Susceptible sheep (n=6) were homozygous for the PrPVQ allele (valine at position 16, glutamine at 171). More resistant sheep were heterozygous possessing one PrPVQ allele and one PrPAR (alanine at position 136 and arginine at position 171). This form of heterozygosity has been shown to confer scrapie resistence in several breeds . Schreuder et al. were able to detect infection in less than half (10 mo) the expected incubation period (25 mo) using tonsil biopsy. The results of the biopsies were subsequently confirmed with immunostaining.

 

List of current tests available for diagnosis of TSE diseases are:

Tests for diagnosis of TSE diseases must be validated for:

Tests for TSE may be affected by:

 

The development of sensitive, reliable tests for BSE infected animals, especially for those with preclinical condition, is a top priority as is the detection of PrP's in food.

Three diagnostic kits have been approved for use in Europe for the detection of BSE and a fourth has been submitted ot the European Commission (EC) for validation. All are antibody based.

Prionics AG (Zurich) has developed the Prionics Check Assay, will distribute through Roche Diagnostics (Basel, Switzerland)

working on blood tests for both BSE and CJD

CEA (Commissariat à l'Energie Atomique; the French Atomic Energy Commission) is distributing its test named Platelia™ through Bio-Rad

Protherics has licensed its assay to Enfer Scientific (Tipperary, U.K.)

EG&G Wallac (Gaithersburg, MD) has developed a test based on the Delfia system

Several other promising tests for live-animal screening are being developed.

The USDA has developed several tests for Scrapie and Chronic Wasting Disease. These new, as yet unapproved tests, offer promises towards detection of TSE in live animals.

The discovery that plasminogen can descriminate between PrPC and PrPSc has lead to interest in developing tests for circulating PrPSc based on this observations. Several companies are actively persuing this market.

Similar to plasminogen binding, synthetic RNA aptamers have been shown to bind PrPC . More recently, Stefan Weiss (CEA) has apparently selected a RNA aptamer that specifically binds PrPSc and not PrPC (reported at the PittCon 2001 Symposium, New Orleans, La, March 4-9,2001). Development of a diagnostic assay is promising.

A molecular marker (expression of an individual gene that shows a unique change) is depressed in spleens of mice, sheep and cattle with TSE compared to controls . The usefulness of this marker (erythroid differentiation-related factor; EDRF) as a preclinical indicator or TSE infection is being explored.

A novel assay that has the potential to indicate the presence of PrPRes within tissues and to identify the strain of TSE has been studied. This assay (Protein-misfolding cyclic amplification; PMCA) is based on the in vitro conversion of PrPC to PrPSc after exposure of PrPC to PrPRes and published by Saborio in Nature 411:810,2001.Click on the image below to learn more about this type of assay.

The PMCA assay.

A new application of the protease resistance test has shown that PrPRes is present in the urine of hamsters, cattle and humans with TSEs but not in the urine of healthy individuals . See BSE_Urine page for further details. UPrPSc was detectable before clinical signs in experiments with hamsters, indicating a strong potential use of this information to develop an early marker of TSE transmission.

 

Several tests for PrP's present in food have been developed.

Bayer Corp. (Research Triangle Park, NC) has joined with BioReliance Corp. (Rockville, MD)

Q-One Biotech (Glasgow, Scotland)

ABC Research Corporation (Gainesville, FL)

R-Biopharm Inc. (Marshall, MI)